Study title:
Krymchantowski-A-V, Filho-P-F-M, Bigal-M-E.
Instituto de Neurologia Deolindo Couto, Rio de Janeiro, Brazil.
Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study.
Cephalalgia : an international journal of headache, {Cephalalgia}, Jul 2006, vol. 26, no. 7, p. 871-4,Krymchantowski-A-V, Filho-P-F-M, Bigal-M-E.
Instituto de Neurologia Deolindo Couto, Rio de Janeiro, Brazil.
Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study.
Cephalalgia : an international journal of headache, {Cephalalgia}, Jul 2006, vol. 26, no. 7, p. 871-4,
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Digestive System Diseases
|
Brands: Please see report, Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: TRIMEBUTINE |
ATC code: A03AA05 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|